How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.

Author: Rebecca Robbins and Sheryl Gay Stolberg